Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs

Joseph E. Harrington, Edbert Hsu

Research output: Contribution to journalArticle

Abstract

To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

Original languageEnglish (US)
Pages (from-to)438-444
Number of pages7
JournalJournal of Health Economics
Volume29
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Pandemics
Pharmaceutical Preparations
Fees and Charges
Human Influenza
Disease Outbreaks
Organizations

Keywords

  • Pandemic
  • Pharmaceutical products
  • Pricing

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Stockpiling anti-viral drugs for a pandemic : The role of Manufacturer Reserve Programs. / Harrington, Joseph E.; Hsu, Edbert.

In: Journal of Health Economics, Vol. 29, No. 3, 05.2010, p. 438-444.

Research output: Contribution to journalArticle

@article{d3f7440e845b4328b03581e6f27234cf,
title = "Stockpiling anti-viral drugs for a pandemic: The role of Manufacturer Reserve Programs",
abstract = "To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.",
keywords = "Pandemic, Pharmaceutical products, Pricing",
author = "Harrington, {Joseph E.} and Edbert Hsu",
year = "2010",
month = "5",
doi = "10.1016/j.jhealeco.2010.02.004",
language = "English (US)",
volume = "29",
pages = "438--444",
journal = "Journal of Health Economics",
issn = "0167-6296",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Stockpiling anti-viral drugs for a pandemic

T2 - The role of Manufacturer Reserve Programs

AU - Harrington, Joseph E.

AU - Hsu, Edbert

PY - 2010/5

Y1 - 2010/5

N2 - To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

AB - To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.

KW - Pandemic

KW - Pharmaceutical products

KW - Pricing

UR - http://www.scopus.com/inward/record.url?scp=77952541303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952541303&partnerID=8YFLogxK

U2 - 10.1016/j.jhealeco.2010.02.004

DO - 10.1016/j.jhealeco.2010.02.004

M3 - Article

C2 - 20236719

AN - SCOPUS:77952541303

VL - 29

SP - 438

EP - 444

JO - Journal of Health Economics

JF - Journal of Health Economics

SN - 0167-6296

IS - 3

ER -